Ozempic vs Wegovy: What’s the Difference?

Ozempic and Wegovy get confused constantly. Pharmacy counters deal with this every day. Patients ask whether their Ozempic is working for weight loss. Others wonder why Wegovy is so much harder to get approved. The answer to most of the confusion is this: Ozempic and Wegovy are the same drug. Different brand, different FDA approval, different dosing, but chemically identical. This post covers what matters about the differences and what does not.

Same Drug, Different FDA Approvals

Both medications contain semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist made by Novo Nordisk. The molecule is identical. What differs is the approved use, marketing, dosing range, and insurance handling.

The FDA prescribing information for Wegovy approves semaglutide for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) plus at least one weight-related condition. It is also approved for adolescents age 12 and older with obesity.

The FDA prescribing information for Ozempic approves semaglutide for type 2 diabetes as an adjunct to diet and exercise, and to reduce cardiovascular event risk in diabetic patients with established cardiovascular disease.

Both approvals are for the same drug. The manufacturer simply runs the clinical trials for each indication and applies for each label separately.

The Dose Difference

This is where Ozempic and Wegovy actually differ practically:

Ozempic dose range: 0.25, 0.5, 1.0, 2.0 mg weekly. Maximum dose for diabetes is 2.0 mg weekly.

Wegovy dose range: 0.25, 0.5, 1.0, 1.7, 2.4 mg weekly. Maximum dose for weight loss is 2.4 mg weekly.

Wegovy has a higher maximum dose (2.4 mg) and an additional intermediate step at 1.7 mg that Ozempic does not have. This is because clinical trials for weight loss found that the 2.4 mg dose produced greater weight loss than 2.0 mg, justifying the addition of the 1.7 and 2.4 mg steps.

For a patient being treated with Ozempic for weight loss at the maximum labeled dose of 2.0 mg, they are slightly under-dosed compared to the maximum labeled weight loss dose of 2.4 mg. In practice, many patients do well on 2.0 mg of Ozempic and do not need the additional increment.

Insurance Coverage: The Real Distinction

The most practical difference between Ozempic and Wegovy is insurance coverage, and it varies by plan:

• Medicare: Covers Ozempic for diabetes. Does not cover Wegovy for weight loss (as of 2025).
• Commercial insurance: Often covers Ozempic for diabetes. Coverage for Wegovy requires prior authorization and often fails.
• Medicaid: Varies by state. Some cover Wegovy under specific criteria.
• Self-pay: Similar retail price for both (roughly 1,000 to 1,350 dollars monthly depending on pharmacy).

This coverage gap drives the off-label prescribing pattern. Many patients who qualify for weight loss medication get Ozempic prescribed because their insurance covers it for diabetes but not Wegovy for weight loss. This is legal when clinically appropriate but creates tension with insurance rules.

Can You Use Ozempic for Weight Loss?

Yes, and it is common practice. Off-label prescribing is legal and widespread when clinically appropriate. Many patients lose significant weight on Ozempic, particularly at the 2.0 mg dose.

Considerations for Ozempic used off-label for weight loss:

• Insurance may still deny coverage if they know the intended use
• Maximum dose is 2.0 mg rather than 2.4 mg, so ceiling is slightly lower
• Clinical outcomes and side effect profile are essentially identical
• Prescriber documentation may frame the clinical rationale appropriately

The FDA permits off-label prescribing based on clinical judgment. What matters for the patient is whether the medication is working and is safe, not whether its label exactly matches the use.

Can You Use Wegovy for Diabetes?

Technically possible and also done off-label in some cases. Wegovy’s maximum dose of 2.4 mg produces strong glucose control effects alongside weight loss.

Considerations:

• Insurance usually prefers Ozempic for diabetes (labeled for that use)
• Cost is essentially identical retail
• Efficacy for diabetes is slightly better at 2.4 mg vs 2.0 mg
• Some patients end up on Wegovy for combined diabetes and obesity indication

In patients with both type 2 diabetes and obesity, either brand can work. Choice often comes down to insurance coverage and available dose range preferences.

What About Rybelsus?

Rybelsus is a third Novo Nordisk product containing semaglutide. Unlike Ozempic and Wegovy, Rybelsus is an oral tablet rather than an injection. It is FDA-approved for type 2 diabetes only.

Rybelsus is not typically used for weight loss because:

• Oral absorption is only about 1 percent vs injection
• Required to be taken first thing in the morning on empty stomach with specific timing requirements
• Lower maximum practical dose than injected forms
• Not labeled for weight loss

Oral semaglutide for weight loss is in development but not yet approved. See our oral vs injectable semaglutide comparison for more detail.

How to Know Which One You Have

Check the pen or vial labeling. Wegovy has distinctive pen designs with blue or teal accents. Ozempic uses different pen design with red or blue markings. The box will clearly say either “Ozempic” or “Wegovy” on the label.

If you fill a prescription and receive something different than expected, check with your pharmacist. Substitution between the two requires a new prescription because they are different branded products even though the active ingredient is identical.

A FDA informational page on semaglutide products provides current guidance on distinguishing the approved formulations from unauthorized compounds or counterfeits.

What About Compounded Semaglutide?

Compounded semaglutide from licensed pharmacies is typically comparable to brand-name Ozempic or Wegovy in active ingredient, though sourcing, quality control, and concentration can vary between compounders.

Most compounded products are not branded as either Ozempic or Wegovy. They are typically labeled simply as “semaglutide” with the concentration specified. The pharmacy provides dosing instructions and the vial for injection.

Whether compounded semaglutide is right for you is a separate decision from Ozempic vs Wegovy. See our compounded vs brand semaglutide post for that analysis.

Switching Between Ozempic and Wegovy

Patients sometimes switch between the two brands. Common reasons:

• Insurance coverage changed
• Starting on Ozempic at 2.0 mg and wanting to try 2.4 mg for more weight loss
• Moving from diabetes management focus to dedicated weight loss focus
• Supply availability at a particular pharmacy

Switching is clinically simple because the drug is the same. You can typically pick up where you left off at the same dose level. Moving from Ozempic 2.0 mg to Wegovy would allow stepping up to 2.4 mg after a typical 4-week interval. Moving the other direction (Wegovy 2.4 mg to Ozempic) requires dropping to 2.0 mg since that is Ozempic’s maximum dose.

Insurance switches often require a new prior authorization. The prescriber’s office typically handles this administrative work.

Ozempic vs Wegovy Price Summary

Approximate monthly costs at 2026 pricing:

• Wegovy retail: 1,300 to 1,400 dollars
• Ozempic retail: 950 to 1,100 dollars
• Wegovy with good insurance: 25 to 200 dollars copay
• Ozempic with diabetes insurance coverage: 25 to 100 dollars copay
• Compounded semaglutide: 200 to 400 dollars self-pay

The price differential between Ozempic and Wegovy is real but usually less important than insurance coverage differential. A Wegovy prescription covered under prior authorization costs less than paying retail for either.

The Practical Summary

Ozempic and Wegovy are the same drug (semaglutide) with different labels. The main practical differences: Wegovy has a higher maximum dose (2.4 mg vs 2.0 mg) and is labeled for weight loss while Ozempic is labeled for diabetes. Insurance coverage often differs significantly. Both can be used off-label for the other indication when clinically appropriate. For most patients, the choice comes down to what insurance covers, what the clinician prescribes, and what is available through their pharmacy or clinic.

• FDA approval. Formal permission to market a drug for specific conditions based on clinical trial evidence. Off-label uses are not prohibited but are not marketed.
• Brand name vs active ingredient. Brand name is the manufacturer’s label (Ozempic, Wegovy). Active ingredient is the actual molecule (semaglutide).
• Off-label prescribing. Legal use of an FDA-approved medication for a condition outside its approval. Common and appropriate when evidence supports use.
• Prior authorization. Insurance requirement for the prescriber to document medical necessity before coverage applies.
• Therapeutic equivalence. When two branded products contain the same active ingredient at the same dose and produce the same clinical effect.